These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Hausdorff WP; Dagan R; Beckers F; Schuerman L Vaccine; 2009 Dec; 27(52):7257-69. PubMed ID: 19833248 [TBL] [Abstract][Full Text] [Related]
11. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy. Madhi SA; Cohen C; von Gottberg A Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016 [TBL] [Abstract][Full Text] [Related]
12. Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule. Wiertsema SP; Kirkham LA; Corscadden KJ; Mowe EN; Bowman JM; Jacoby P; Francis R; Vijayasekaran S; Coates HL; Riley TV; Richmond P Vaccine; 2011 Jul; 29(32):5163-70. PubMed ID: 21621576 [TBL] [Abstract][Full Text] [Related]
13. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Tocheva AS; Jefferies JM; Rubery H; Bennett J; Afimeke G; Garland J; Christodoulides M; Faust SN; Clarke SC Vaccine; 2011 Jun; 29(26):4400-4. PubMed ID: 21504773 [TBL] [Abstract][Full Text] [Related]
14. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Poolman J; Borrow R Expert Rev Vaccines; 2011 Mar; 10(3):307-22. PubMed ID: 21434799 [TBL] [Abstract][Full Text] [Related]
15. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life. Silfverdal SA; Skerlikova H; Zanova M; Papúchová D; Traskine M; Borys D; Schuerman L Pediatr Infect Dis J; 2011 Sep; 30(9):e155-63. PubMed ID: 21572373 [TBL] [Abstract][Full Text] [Related]
16. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease. Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982 [TBL] [Abstract][Full Text] [Related]
18. Implication of pneumococcal conjugate vaccines to public health: Thailand perspective. Wongsawat J; Chokephaibulkit K J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S53-60. PubMed ID: 21294383 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452 [TBL] [Abstract][Full Text] [Related]
20. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Musher DM; Sampath R; Rodriguez-Barradas MC Clin Infect Dis; 2011 Mar; 52(5):633-40. PubMed ID: 21292668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]